Promis Neurosciences (PMN) Competitors $0.42 -0.02 (-4.89%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.01 (+2.53%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. MGNX, SAVA, COYA, IPA, SKYE, IFRX, HLVX, SRZN, ONCY, and EQShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include MacroGenics (MGNX), Cassava Sciences (SAVA), Coya Therapeutics (COYA), ImmunoPrecise Antibodies (IPA), Skye Bioscience (SKYE), InflaRx (IFRX), HilleVax (HLVX), Surrozen (SRZN), Oncolytics Biotech (ONCY), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors MacroGenics Cassava Sciences Coya Therapeutics ImmunoPrecise Antibodies Skye Bioscience InflaRx HilleVax Surrozen Oncolytics Biotech Equillium MacroGenics (NASDAQ:MGNX) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Do analysts rate MGNX or PMN? MacroGenics currently has a consensus target price of $3.60, suggesting a potential upside of 130.77%. Promis Neurosciences has a consensus target price of $4.33, suggesting a potential upside of 935.69%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MGNX or PMN? In the previous week, MacroGenics had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.45 beat MacroGenics' score of 1.15 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment MacroGenics Positive Promis Neurosciences Positive Is MGNX or PMN more profitable? Promis Neurosciences has a net margin of 0.00% compared to MacroGenics' net margin of -21.99%. MacroGenics' return on equity of -40.24% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-21.99% -40.24% -14.62% Promis Neurosciences N/A -266.69%-131.59% Which has better earnings & valuation, MGNX or PMN? Promis Neurosciences has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$163.87M0.60-$66.97M-$0.57-2.74Promis NeurosciencesN/AN/A$2.78M-$0.21-1.99 Which has more risk and volatility, MGNX or PMN? MacroGenics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Do institutionals and insiders have more ownership in MGNX or PMN? 96.9% of MacroGenics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 13.0% of MacroGenics shares are held by insiders. Comparatively, 6.1% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMacroGenics and Promis Neurosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.68M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.9921.3874.9226.41Price / SalesN/A243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book0.849.6413.256.28Net Income$2.78M-$53.20M$3.29B$270.38M7 Day Performance-4.26%0.44%0.47%2.70%1 Month Performance-32.19%4.26%4.59%5.99%1 Year Performance-65.98%9.43%73.41%25.94% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences3.6673 of 5 stars$0.42-4.9%$4.33+935.7%-64.2%$21.68MN/A-1.995Positive NewsShort Interest ↓MGNXMacroGenics4.4354 of 5 stars$1.74-1.7%$3.60+106.9%-57.0%$111.87M$149.96M-3.05430High Trading VolumeSAVACassava Sciences2.5348 of 5 stars$2.27-0.4%$2.00-11.9%-92.5%$110.14MN/A-0.8930Positive NewsCOYACoya Therapeutics2.9616 of 5 stars$6.52-0.6%$16.50+153.1%-5.5%$109.72M$3.55M-5.266Gap UpIPAImmunoPrecise Antibodies2.6251 of 5 stars$1.93-18.6%$4.00+107.3%+212.7%$109.39M$17.59M-2.8480Gap DownSKYESkye Bioscience2.0613 of 5 stars$3.38-3.4%$15.50+358.6%-29.2%$108.46MN/A-3.1911IFRXInflaRx3.0952 of 5 stars$1.75+9.4%$6.20+254.3%-11.9%$107.41M$180K-2.1960Short Interest ↓Gap UpHigh Trading VolumeHLVXHilleVax1.5945 of 5 stars$2.08-0.5%$2.00-3.8%+14.2%$104.79MN/A-1.4520Positive NewsShort Interest ↑SRZNSurrozen2.9833 of 5 stars$12.32+1.1%$38.50+212.5%+34.8%$104.43M$10.65M-0.8580Positive NewsGap DownONCYOncolytics Biotech2.4087 of 5 stars$1.15+10.6%$5.00+334.8%+33.9%$104.38MN/A-4.2630Gap UpEQEquillium0.7641 of 5 stars$1.72-1.1%$1.00-41.9%+114.9%$103.54M$41.10M-3.0740Short Interest ↓Gap Down Related Companies and Tools Related Companies MacroGenics Alternatives Cassava Sciences Alternatives Coya Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Skye Bioscience Alternatives InflaRx Alternatives HilleVax Alternatives Surrozen Alternatives Oncolytics Biotech Alternatives Equillium Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
